Close menu




Health

Photo credits: pixabay.com

Commented by Jens Castner on November 20th, 2026 | 05:55 CET

Invest now, cash in later: Deutsche Telekom, RE Royalties and Fresenius on a growth trajectory

  • Growth
  • Health
  • Telecommunications
  • Renewable energies
  • Fresenius
  • RE Royalties
  • Deutsche Telekom
  • Fibre optics
  • Mobile communications
  • Wind power
  • Solar

In turbulent stock markets, investors seek stability. Dividend stocks are often seen as a rock in a storm: the payout provides a sense of security, regardless of what the share price is doing. But even a rock can develop cracks. Even a long-standing dividend aristocrat like Fresenius had to suspend its dividend once in recent years – and emerged stronger as a result. Sometimes, voluntarily forgoing a payout is the better choice. Deutsche Telekom cut its dividend to invest in growth, thereby jolting its share price out of its lethargy. RE Royalties is now taking a similar approach.

Read

Commented by Armin Schulz on November 4th, 2026 | 05:33 CET

Stocks for Healthier Harvests – Novo Nordisk, MustGrow Biologics and Nestlé at the Intersection of Appetite and Agriculture

  • Novo Nordisk
  • MustGrow Biologics
  • Nestle
  • Obesity
  • Diabetes
  • healthy living
  • organic farming
  • Mustard extract
  • Biofertiliser
  • Biological crop protection
  • Health Science
  • Food supplements

Created and published on behalf of MustGrow Biologics Corp.

Living a healthier life today also means managing one's appetite medically. People who lose weight change their eating habits and pay closer attention to where their food comes from. This brings agricultural land into focus, as it is there that the foundations are laid for producing healthy crops for consumers. At the end of October, a provider of biological crop protection products reported successful field trials in Europe. At the end of the value chain is the food group that turns harvested crops into products for health-conscious consumers. We therefore take a closer look at Novo Nordisk, MustGrow Biologics and Nestlé.

Read

Commented by Tarik Dede on October 30th, 2026 | 13:54 CET

Pharma as a defensive alternative: Eli Lilly, Formycon and GSK in focus

  • Pharma
  • Health
  • Weight-loss injection
  • Generics
  • GSK
  • Formycon
  • Biosimilars
  • Eli Lilly

This year we have repeatedly seen major rotations, particularly in the US equity markets. When AI stocks weakened, other sectors, such as utilities and pharma, performed well. No real money was withdrawn from the markets in the process. Pharma stocks could be among the big winners if the major indices suffer a serious crash. An end to the AI boom, for example, would be a disaster for investors and market participants. Investors looking to gradually adopt a more defensive position should consider adding healthcare stocks to their portfolio. In the past, this strategy has certainly often proved its worth. Today we therefore look at the shares of Formycon, Eli Lilly and GSK.

Read

Commented by Jens Castner on October 30th, 2026 | 05:45 CET

When the stock market gets it wrong: Schott Pharma clears its name; Lahontan Gold and Instone are the next candidates

  • Speciality glass
  • Gold
  • Real estate
  • Chemicals
  • Silver
  • Expropriation
  • Health
  • Berlin
  • Misvaluations
  • Mining
  • Schott Pharma
  • Instone Real Estate
  • Lahontan Gold

Markets are quick to judge, and often paint companies with a broad brush. When one company runs into difficulties, its competitors immediately come under suspicion too. Schott Pharma has already been through this and dispelled the doubts with strong figures. Its share price is recovering. For Lahontan Gold and Instone Real Estate, the recovery has yet to come. The Canadian gold explorer is being punished alongside the major producers, while the property developer is being grouped with Berlin's residential landlords. In both cases, the facts tell a different story. The share price upside is considerable.

Read

Commented by Lars Winter on October 24th, 2026 | 05:29 CEST

New Orders, a New Shareholder and a New Bid: Fresh Developments at HPQ Silicon, CTS Eventim and Qiagen

  • Hydrogen
  • Drones
  • Defence
  • Health
  • Concerts
  • Ticketing
  • HPQ Silicon
  • CTS Eventim
  • Qiagen
  • Batteries

Created and published on behalf of HPQ Silicon

Sometimes a single announcement is enough to reshape the story behind a stock. At HPQ Silicon, certified high-performance cells and initial orders could mark the transition from a development project to a commercial supplier. At CTS Eventim, the arrival of an activist investor has sparked fresh interest. At Qiagen, meanwhile, a takeover offer could lead to a bidding war between two financial investors. Three shares, three potential share price drivers – but also three very different risk and reward profiles. We take a closer look at the trio in our stock review.

Read

Commented by Lars Winter on October 20th, 2026 | 05:44 CEST

Gold, Money and Healthcare: Lahontan Gold, Goldman Sachs and Johnson & Johnson – 3 Promising Stocks Under Review

  • Gold
  • Gold mine
  • Gold price
  • Commodities
  • Precious metal
  • Mining
  • Banks
  • Financial services providers
  • Pharmaceutical industry
  • Medicines
  • Health
  • Medicine

Canadian gold exploration company Lahontan Gold is generating optimism. A preliminary economic assessment of its key mining project in Nevada recently assigned the Santa Fe Mine a calculated project value of USD 820 million. This is a multiple of its current market capitalisation, giving the stock considerable upside potential. Goldman Sachs has also surprised the market in recent days with a strong set of financial results. Pharmaceutical giant Johnson & Johnson, meanwhile, raised its outlook despite one minor setback. Three promising companies with positive news are under review.

Read

Commented by Lars Winter on October 12th, 2026 | 05:45 CEST

Almonty, 2G Energy and Redcare Pharmacy: Three Exciting Stocks with Fresh Momentum

  • Almonty
  • Tungsten
  • Commodities
  • 2G Energy
  • Energy
  • Heat Pumps
  • Redcare Pharmacy
  • Medicines
  • Health
  • Medicine

New orders, higher forecasts, and the transition from project developer to producer: The news outlook for Almonty Industries, 2G Energy, and Redcare Pharmacy has improved significantly recently. The three companies serve completely different markets. What they have in common is that they must now translate high expectations into measurable growth. We take a closer look at these three stocks.

Read

Commented by Nico Popp on September 16th, 2026 | 06:55 CEST

The End of Weight-Loss Shots? Innovations at Merck and Novo Nordisk—BioNxt Solutions Poised for a Hot Fall?

  • Biotechnology
  • Biotech
  • Innovations
  • Obesity
  • weightloss
  • Health

The battle against excess weight is no longer merely a lifestyle issue. Medical professionals now view extreme obesity as a chronic disease that weakens the body and can lead to serious cardiovascular conditions, as cardiological studies have shown. By contrast, sustained weight loss can help pave the way to a longer, healthier life. This insight, combined with pharmaceutical innovation, has sparked an unprecedented race to develop weight-loss drugs. Companies are searching for the ideal way to boost metabolism while making medication as easy and convenient to take as possible.

Read

Commented by Jens Castner on August 27th, 2026 | 07:15 CEST

Like a Phoenix Rising from the Ashes: Deutsche Telekom, Almonty and Abbott Are Back on Track

  • Tungsten
  • CriticalMetals
  • Defense
  • Telecommunications
  • Healthcare

For months, Deutsche Telekom, Almonty Industries, and Abbott Laboratories were headed in only one direction: down. Then the quarterly results came in—and with them, a breakthrough. For Deutsche Telekom and Almonty, a combination of growth and share buybacks sparked the initial rally; for Abbott, it was the confirmation that two negative one-time effects were only temporary. A sustained breakout from the downtrend is now a reality for all three stocks. How far is the road back to previous highs, and where do analysts even see potential for new all-time highs?

Read

Commented by Tarik Dede on August 11th, 2026 | 07:20 CEST

Pharma and Biotech Stocks in the Spotlight: Moderna, BioNxt Solutions, and Eli Lilly

  • Biotechnology
  • Pharma
  • Biotech
  • Healthcare
  • Obesity
  • Cancer

Many patents held by the major pharmaceutical giants are set to expire in the coming years. Once that protection is gone, companies face the risk of lost revenue due to copycat drugs, known as generics. Consequently, the stakes are currently very high in the industry. Acquisitions and massive investments in the research pipeline are shaping the landscape. The markets for oncology and weight-loss injections are particularly lucrative. The former is a matter of life and death, while the latter is mostly about appearance and health. At the same time, many countries need to reduce their healthcare costs. Demographic trends and many lifestyle-related diseases are taking their toll on people and health insurance premiums. For investors, this tension presents a wealth of opportunities. We are therefore taking a look today at the stocks of Moderna, BioNxt Solutions, and Eli Lilly.

Read